CLINICAL TRIALS PROFILE FOR BISOPROLOL FUMARATE
✉ Email this page to a colleague
All Clinical Trials for BISOPROLOL FUMARATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00702156 ↗ | Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease | Terminated | NHS Greater Glasgow and Clyde | Phase 2 | 2005-03-01 | The principal research objectives are to demonstrate cardioselective beta-blockade using bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality of life in patients with heart failure and coexistent moderate or severe chronic obstructive pulmonary disease with or without significant reversibility. Patients will be followed up for 4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated dose. Health status will be assessed using a generic and two disease specific questionnaires, and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise testing. |
| NCT01741623 ↗ | Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition | Completed | IPCA Laboratories Ltd. | Phase 1 | 2012-08-01 | This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult human subjects. |
| NCT01744873 ↗ | Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition | Completed | IPCA Laboratories Ltd. | Phase 1 | 2012-08-01 | This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult human subjects. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03779646 ↗ | Bisoprolol in DMD Early Cardiomyopathy | Recruiting | Chinese Academy of Medical Sciences | Phase 2/Phase 3 | 2019-01-16 | This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BISOPROLOL FUMARATE
Condition Name
Clinical Trial Locations for BISOPROLOL FUMARATE
Clinical Trial Progress for BISOPROLOL FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for BISOPROLOL FUMARATE
Sponsor Name
